Novel Heteroaromatic Carboxamides as Plasma Kallikrein Inhibitors for Treating Diabetic Complications, Ocular Diseases, and Edema-Associated Diseases.

ID: ALA4831551

Journal: ACS Med Chem Lett

Title: Novel Heteroaromatic Carboxamides as Plasma Kallikrein Inhibitors for Treating Diabetic Complications, Ocular Diseases, and Edema-Associated Diseases.

Authors: Sabnis RW.

Abstract: In targeted protein degradation of kinases, key discoveries have been made specifically involving selective kinase degradation. Structural and biophysical studies on the ternary complex formation have provided a clear understanding of the basis for achieving degradation selectivity which is important in guiding the design of efficient and selective protein degraders.

CiteXplore: 34795850

DOI: 10.1021/acsmedchemlett.1c00530

Patent ID: ┄